Feldman, Howard
- University of California, San Diego · Neurosciences (NIH department code)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #2,570
- Rising Star
- R01 Holder
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2015 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2023 award categories
- Neurosciences
NIH Funding · FY2023
Linked Award Amount
$2.5M
Full award amounts, FY2023
Award Records
1
Records listing this PI
Award-Linked Rank
#2,570
By linked amount among FY2023 PIs
Earliest Year Loaded
2015
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Feldman, Howard as a PI. Multi-PI records show the full award amount for context.
- 5R01AG061146-04R01Contact PIA Seamless Phase 2A-B Randomized Double Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of PQ 912 in Patients with Early Alzheimer's DiseaseUniversity of California, San Diego · Neurosciences (NIH department code)$2.5Maward amount
Award organization
Organizations that administered FY2023 awards listing Feldman, Howard as a PI.
FY2023 award administered by University of California, San Diego (CA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2015First NIH AwardUniversity of California, San Diego
- 2015$500K Cumulative Funding
- 2015Entered Top 50% NationallyRanked #9204
- 2016$1M Cumulative Funding
- 2016$2M Cumulative Funding
- 2016$5M Cumulative Funding
- 2016$10M Cumulative Funding
- 2016Entered Top 25% NationallyRanked #172
- 2016Entered Top 10% NationallyRanked #172
- 2016Entered Top 5% NationallyRanked #172
- 2016Entered Top 1% NationallyRanked #172
- 2017$25M Cumulative Funding
- 2017R01 Grant Holder
- 2022$50M Cumulative Funding